Advanced Medical Solutions Grp PLC Total Voting Rights (2369O)

TIDMAMS

RNS Number : 2369O

Advanced Medical Solutions Grp PLC

29 September 2023

29 September 2023

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Total Voting Rights

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 29 September 2023 comprises 217,228,104 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

   -     Ends - 

For further information, please visit www.admedsol.com or contact:

 
 Advanced Medical Solutions Group plc            Tel: [phone] 
                                                            545508 
 Chris Meredith, Chief Executive Officer 
  Eddie Johnson, Chief Financial Officer 
  Michael King, Investor Relations 
 
 ICR Consilium Strategic Communications       Tel: [phone] 
                                                              5700 
 Matthew Neal / Lucy Featherstone          [e-mail] 
 
 Investec Bank plc ( NOMAD and Broker )       Tel: [phone] 
                                                              5970 
 Gary Clarence / David Anderson 
 
  HSBC Bank plc (Broker)                       Tel: [phone] 
  Sam McLennan / Joe Weaving / Stephanie                      8888 
  Cornish 
 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) . AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal(R) brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products, AFS Medical, an Austrian a specialist surgical business with a focus on minimally invasive procedures, and Connexicon Medical, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France, Ireland and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREASNNADSDEFA

(END) Dow Jones Newswires

September 29, 2023 11:38 ET (15:38 GMT)